391 related articles for article (PubMed ID: 10829350)
1. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine (Exelon) for Alzheimer's disease.
Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
[No Abstract] [Full Text] [Related]
3. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Schölzel-Dorenbos CJ
Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
[No Abstract] [Full Text] [Related]
4. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
6. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
8. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
9. [Acetylcholinesterase inhibitors].
Rioux S
Rev Med Suisse Romande; 2003 Jul; 123(7):471-4. PubMed ID: 15088511
[TBL] [Abstract][Full Text] [Related]
10. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
12. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
13. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine for Alzheimer's disease.
Desai AK; Grossberg GT
Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
[TBL] [Abstract][Full Text] [Related]
15. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
[TBL] [Abstract][Full Text] [Related]
16. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine: new product. No better than donepezil.
Prescrire Int; 1999 Apr; 8(40):47-8. PubMed ID: 10848060
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
[TBL] [Abstract][Full Text] [Related]
20. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
[No Abstract] [Full Text] [Related]
[Next] [New Search]